proteasome

(redirected from Ubiquitin proteasome system)
Also found in: Dictionary, Encyclopedia.
Related to Ubiquitin proteasome system: Ubiquitin proteasome pathway, Ubiquitylation, Immunoproteasome

pro·te·a·some

(prō'tē-ă-sōm),
Cytoplasmic organelle, composed of a cylindric core particle bound by two regulatory particles at each end, responsible for degrading endogenous proteins. Proteins to be destroyed are recognized by proteasomes because of the presence of ubiquitin conjugated to the targeted protein's lysine residue.
See also: ubiquitin-protease pathway.
[protease + -some ]

proteasome

(prō′tē-ə-sōm′)
n.
A cellular protein complex consisting of proteolytic enzymes that degrade endogenous proteins, especially those that are damaged, pathogenic, or no longer of use.

proteasome

, proteosome (prō′tē-ă-sōm″)
An enzymatic (protease) cell organelle that degrades misfolded or damaged proteins and modulates the quantity of regulatory proteins in the cell. The breakdown of proteins by proteasomes (proteolysis) is triggered when damaged proteins are tagged by ubiquitin.

Proteasome

A large, cylindrical protein complex of several sub-units, present in the cytoplasm and nucleus of all cells and an essential component in cell metabolism. The function of the proteasome is to act as a kind of shredder, degrading unwanted proteins that have been tagged for destruction with UBIQUITIN chains. It strips proteins of their ubiquitin, unfolds them and catalyzed them to peptides. Proteasomes have aroused much interest as therapeutic trargets in cancer. The proteasome 26S is involved both in the induction and repression of APOPTOSIS. See also POLYUBIQUITINATION.
References in periodicals archive ?
These cytokines would activate IKK complex, leads to the release of NF-KB, and subsequently binding to DNA, resulting in activation of the proteolytic ubiquitin proteasome system and the breakdown of skeletal muscle (Murphy and Lynch 2009; Reid and Li 2001).
The ubiquitin proteasome system in the central nervous system; from physiology to pathology; 2008 update.
At this year's conference, Scotland will present a panel on 'The Ubiquitin Story,' a look at an exciting new research area in which Scotland has invested heavily through the $15 million Scottish Institute for Cell Signaling (SCILLS) and the $14 million ITI Life Sciences Ubiquitin Proteasome System (UPS) drug discovery program.

Full browser ?